RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-227

Silviu said at the end of May 2021:

COVID RESULTS EXCITE

BUT HE IS MOST EXCITED ABOUT THE COVID APPLICATIONS, DESPITE THE TRIAL SETBACK IN DECEMBER.

MESOBLAST RECENTLY TOLD INVESTORS THE LATEST TRIAL RESULTS SHOWED COVID PATIENTS AGED UNDER 65 RECEIVING REMESTEMCEL-L HAD REDUCED MORTALITY FOR 60 DAYS AFTER TAKING THE DRUG. THOSE USING MESOBLAST’S DRUG SAW 46 PER CENT LOWER MORTALITY THROUGH TO DAY 50 OF THE TREATMENT.

WHEN USED IN COMBINATION WITH THE STANDARD COVID-TREATING STEROID KNOWN AS DEXAMETHASON, REMESTEMCEL-L LOWERED MORTALITY BY 75 PER CENT AND INCREASED DAYS ALIVE WITHOUT MECHANICAL VENTILATION IN SUBJECTS AGED UNDER 65. NO TEST DATA WAS RELEASED FOR PATIENTS AGED OVER 65.

“THE SURVIVAL BENEFIT WE ARE NOW SEEING IS BEYOND MY WILDEST DREAMS,” ITESCU SAYS.

“ON THAT BASIS WE ARE GOING TO HAVE A CONVERSATION WITH THE FDA OVER THE NEXT COUPLE OF MONTHS TO SEE IF WE HAVE SUFFICIENT DATA POINTS FOR AN EMERGENCY USE AUTHORISATION. OR WHETHER THEY WANT ANOTHER TRIAL.”
______________________________________________________

We shall probably be hearing soon about the CONFIRMATORY COVID ARDS trial and possible new partner. My bet is we hear something before the scheduled upcoming conference call with analysts in two weeks time.